– The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Webinars – – Society of Neuroscience 50th Anniversary Meeting – BETHESDA, Md., Oct. 28, 2021 (GLOBE …
Dr. Luca Benatti to Chair SAB BETHESDA, Md., Oct. 26, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “company”), a biotechnology …
BETHESDA, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing …
Conference Dates: September 27th-30th BETHESDA, Md., Sept. 23, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused …
– Conference Dates: September 20th-23rd – BETHESDA, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology …
BETHESDA, Md., Sept. 09, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing …
GT-02287and GT-02329 compounds display positive effects on GCase activity and related parameters — Study results demonstrate an increase in GCase protein levels with transport to …
BETHESDA, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing …
Announced Multi-Target Drug Discovery Collaboration with Zentalis Pharmaceuticals in Oncology — Granted Two Patents for Compounds that Stabilize G-Case for Gaucher’s Disease and other Synucleinopathies …
BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and …
Activity of GBA and GALC Enzymes Play Key Roles in the Neurodegenerative Diseases and Lysosomal Storage Diseases BETHESDA, Md., June 10, 2021 (GLOBE NEWSWIRE) — …
BETHESDA, Md., May 27, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and …
BETHESDA, Md., May 17, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and …
Completed successful initial public offering and raised $46 million in gross proceeds — Appointed four new independent board of directors to strengthen leadership team — …
Compounds reverse the neurodegenerative process observed in a Parkinson’s disease in vivo model Compounds are novel allosteric regulators that bind, stabilize and restore activity of …
BETHESDA, Md., April 27, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and …
Abstract highlighting Gain’s STAR candidate for Parkinson’s disease selected as one of the 10 Best Abstracts at the conference BETHESDA, Md., April 22, 2021 (GLOBE …
Collaboration to use Gain’s proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) computational platform technology to identify new and previously difficult-to-drug oncology targets BETHESDA, Md., April 20, …
BETHESDA, Md., March 25, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain”) today announced the closing of its initial public offering of 3,636,364 shares of …
BETHESDA, Md., March 18, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain”) today announced the pricing of its initial public offering of 3,636,364 shares of …
10 Mar: Gain Therapeutics Files Registration Statement with SEC for Proposed Initial Public Offering
BETHESDA, Md., March 10, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain”) today announced that it has launched the roadshow for its initial public offering …
STAR candidates for the treatment of Gaucher Disease enhance GCase activity in a neuronal cell model and reduce toxic accumulation of GCase substrate STAR candidates …
BETHESDA, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric …
BETHESDA, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain”) today announced the addition of Dov Goldstein, M.D., Gwen Melincoff, Claude Nicaise, M.D. …
– Researchers will further develop the Site-directed Enzyme Enhancement Therapy (SEE-Tx)™ technology for the treatment of rare genetic and neurodegenerative diseases – The collaborative agreement …
Partnership to investigate Gain’s structurally targeted allosteric regulator candidates (STARs) in cellular models of Gaucher disease and Parkinson’s disease November 30, 2020 09:40 ET | …
October 13, 2020 08:00 ET | Source: Gain Therapeutics BETHESDA, Md., Oct. 13, 2020 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused …
Collaboration to Focus on Rare Genetic and Demyelinating Diseases, Including Lysosomal Storage Diseases September 10, 2020 08:00 ET | Source: Gain Therapeutics BETHESDA, Md., Sept. …
September 12, 2019 02:30 AM Eastern Daylight Time LUGANO, Switzerland–(BUSINESS WIRE)–Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes …
July 21, 2020 08:00 ET | Source: Gain Therapeutics Financing intended to accelerate IND-enabling studies of allosteric drug candidates for rare genetic and neurodegenerative diseases, …